Munich Life Science Pitch Day: The 6th Edition

## **Innovative Drug Development Projects at the 6th Munich Life Science Pitch Day**

Join us as we recap the highlights of the 6th Munich Life Science Pitch Day, where groundbreaking drug development projects were presented to over 20 investors. Organized in cooperation with High-Tech Gründerfonds, Bayer AG, Boehringer Ingelheim, and the IZB, this annual event showcases the best and brightest in the life science sector.

This year, 35 project teams from the life science sector applied, and 10 start-ups were selected to present their innovative drug development projects to renowned venture capital companies. From fighting cancer to developing revolutionary therapies for neurodegeneration and Alzheimer’s disease, these projects have the potential to shape the future of healthcare.

The event was moderated by Dr. Martin Pfister, a principal of HTGF, who provided insights into the world of venture capital. Dr. Peter Hanns Zobel, Managing Director of the IZB, also gave a glimpse into the dynamic Start-Up Center IZB, while Dr. John-Edward Butler-Ransohoff, Vice President Open Innovation – Public Private Partnership at Bayer AG, explained the various cooperation models at Bayer AG. A fireside chat with Dr. Martin Pfister and Dr. Ingmar Hoerr, founder of CureVac AG, further engaged the participants.

Among the venture capital firms in attendance were industry leaders such as Abbvie, Apollo Health Ventures, BioMed Partners, and Forbion Capital Partners, to name a few. Their enthusiasm for the innovative drug developers was evident, as they listened intently to the presentations and engaged in fruitful discussions.

Here are the 10 project teams that presented at the “6th Munich Life Science Pitch Day”:

1. Dimericon, Ulrich Kessler: Fighting cancer – A novel therapeutic modality conquering the plasticity conundrum in IDP-targeted oncology drug discovery.
2. Fundamental Pharma, Thomas Schulze: Next-generation brain drugs acting as molecular spacers to halt neurodegeneration.
3. FUSIX Biotech, Jennifer Altomonte: A TUM spin-off developing a “best-in-class” oncolytic virus platform to treat solid tumors.
4. Galimedix, Alexander Gebauer: Breakthrough therapy in Alzheimer’s disease: Small molecule GAL-201 for cognitive improvement and neuroprotection.
5. Intellexon, Christoph Winterhalter: Intellexon uncovered new embryo-fetal HLAs as unique tumor targets.
6. Invasight, Karthiga Santhana Kumar: Developing potent and safe first-in-class, protein-protein interaction inhibitors against invasive cancers.
7. OPSYON, Nadja Fenn: OPSYON’s vision and mission are to combine direct cancer cell targeting with the benefits of immune checkpoint inhibition in one molecule to maximize anti-cancer efficacy while minimizing unwanted side effects.
8. RecTec, Anne-Kristin Heninger: It is our vision to establish designer recombinases as the leading technology for safe and precise genome surgery to cure genetic diseases.
9. Riana Therapeutics, Anna Orlova: We develop novel first-in-class treatment options against cancer.
10. Sirana Pharma, Hermann-Josef Kaiser: Restoring musculoskeletal health.

Witness the cutting-edge innovations and groundbreaking research presented at the 6th Munich Life Science Pitch Day. Stay tuned for more updates on these game-changing projects that have the potential to revolutionize the field of medicine.

Innovative drug developers presented to over 20 investors at the Munich Start-Up Center

The 6th Munich Life Science Pitch Day was organized in cooperation with High-Tech Gründerfonds, Bayer AG, Boehringer Ingelheim and the IZB

Once again the Munich Life Science Pitch Day on the September 30, 2001 in Munich was a total success for both the project teams and the more than 20 investors. This event takes place every year in cooperation with High-Tech-Gründerfonds (HTGF), Bayer AG, Boehringer Ingelheim and the Innovation and Start-Up Center for Biotechnology (IZB) in Martinsried near Munich. 35 project teams from the life science sector had applied. Ten start-ups had the opportunity to present their innovative drug development projects to renowned venture capital companies. Dr. Martin Pfister, principal of HTGF moderated the event and introduced the HTGF. Dr. Peter Hanns Zobel, Managing Director of the IZB, gave a glimps into the dynamic Start-Up Center IZB. Dr. John-Edward Butler-Ransohoff, Vice President Open Innovation – Public Private Partnership, Bayer AG explained what kinds of cooperation models exist at Bayer AG. The participants followed the fireside chat with Dr. Martin Pfister and Dr. Ingmar Hoerr, founder of CureVac AG with great interest.

The following venture capital firms attended this event: Abbvie, Apollo Health Ventures, Bayer, Bayern Capital, BioMed Partners, bmp Ventures, Boehringer Ingelheim, Coparion, Forbion Capital Partners, Hadean Ventures, HTGF, KURMA Partners, Long VC, LSP, mbc, Maximon, Medi Ventures, Occident Group, Seventure, TVM Capital, Vantage Value, Vesalius Biocapital and Wellington Partners.

The investors were enthusiastic about the innovative drug developers. The following project teams presented at the “6th Munich Life Science Pitch Day”:
1. Dimericon, Ulrich Kessler: Dimericon, Ulrich Kessler: Fighting cancer – A novel therapeutic modality conquering the plasticity conundrum in IDP-targeted oncology drug discovery

2. Fundamental Pharma, Thomas Schulze: Next generation brain drugs acting as molecular spacers to halt neurodegeneration

3. FUSIX Biotech, Jennifer Altomonte: A TUM spin-off developing a “best-in-class” oncolytic virus platform to treat solid tumors

4. Galimedix, Alexander Gebauer: Breakthrough therapy in Alzheimer´s disease:
Small molecule GAL-201 for cognitive improvement and neuroprotection

5. Intellexon, Christoph Winterhalter: Intellexon uncovered new embryo-fetal HLAs as unique tumor targets

6. Invasight, Karthiga Santhana Kumar: Developing potent and safe first-in-class, protein-protein interaction inhibitors against invasive cancers

7. OPSYON, Nadja Fenn: OPSYON’s vision and mission is to combine direct cancer cell targeting with the benefits of immune checkpoint inhibition in one molecule to maximize anti-cancer efficacy while minimizing unwanted side effects.

8. RecTec, Anne-Kristin Heninger: It is our vision to establish designer recombinases as the leading technology for safe and precise genome surgery to cure genetic diseases.

9. Riana Therapeutics, Anna Orlova: We develop novel first-in-class treatment options against cancer

10. Sirana Pharma, Hermann-Josef Kaiser: Restoring musculoskeletal health